ComplianceOnline

Conducting Effective Investigations of Out of Specification and Atypical Laboratory Results

Instructor: Gregory Martin
Product ID: 702360
  • 27
  • April 2017
    Thursday
  • 10:00 AM PDT | 01:00 PM EDT
    Duration: 120 Min

Live Online Training
April 27, Thursday 10:00 AM PDT | 01:00 PM EDT | Duration: 120 Min

$199.00
One Dial-in One Attendee
$449.00
Group-Max. 10 Attendees/Location
(For multiple locations contact Customer Care)

recorded version

$249.00
1x Person - Unlimited viewing for 6 Months
(For multiple locations contact Customer Care)
Recorded Link and Ref. material will be available in My CO Section 48 hrs after completion of Live training

Training CD

$349.00
One CD is for usage in one location only.
(For multiple locations contact Customer Care)
CD and Ref. material will be shipped within 15 business days after completion of Live training

Combo Offers

Live + Recorded Version

$349.00

Live + Training CD

$449.00

Customer Care

Fax: +1-650-565-8542

Email: customercare@complianceonline.com

Read Frequently Asked Questions

This training on pharmaceutical laboratory OOS investigations will explain how to recognize and address atypical or out of specification results, using approaches which have been recommended by regulatory authorities, performing appropriate investigations.

Why Should You Attend:

Upon completion of this course the attendee should:

  1. Be familiar with various terms associated with investigations of atypical or out of specification results, and how to document those investigations.
  2. Be familiar with the FDA Guidance for Industry on Investigating Out-of-Specification (OOS) Test Results for Pharmaceutical Production and how to apply it in laboratory situations.
  3. Be able to create a Laboratory Investigation Checklist and effectively document an investigation, including rationale and results.
  4. Know the importance of Corrective and Preventative Action (CAPA) and be able to identify appropriate CAPAs.
  5. Understand practical strategies to utilize outcomes from investigations for continuous improvement and reduction of future OOS results.

Areas Covered in the Seminar:

  • What Constitutes An Atypical or Out of Specification Result?
  • The Barr Decision of 1993 and Its Impact on OOS Investigations.
  • The FDA Guidance for Industry on Investigating OOS Test Results.
  • Reporting Data.
  • Conducting the Investigation.
    • Creating an Investigation Checklist
    • Considering Other Batches
    • Retesting
  • Evaluating the Outcomes:  Is there an assignable cause?
  • Documenting the Investigation.
  • Utilizing Outcomes for Continuous Improvement.
  • Questions and Discussions.

Who Will Benefit:

The following personnel in pharmaceutical laboratories will benefit from this training:

  • Chemists
  • Supervisors and Managers
  • Quality Assurance Personnel responsible for generating or evaluating test results in a regulated environment
  • GMP auditors
  • Analysts and other laboratory staff
  • Regulatory Affairs
Instructor Profile:
Gregory Martin

Gregory Martin
Founder and President, Complectors Consulting LLC

Gregory Martin is president of Complectors Consulting, which provides consulting and training in the area of pharmaceutical analytical chemistry. Mr. Martin has over 25 years’ experience in the pharmaceutical industry and was director of pharmaceutical analytical chemistry (R&D) for a major pharma company for a number of years. In addition, he has volunteered for the USP for over 10 years, and currently serves as vice chair of the General Chapters – Physical Analysis Expert Committee, and serves on expert panels on validation and verification, weights and balances, residual solvents and use of enzymes for dissolution testing of gelatin capsules.

He has particular interest in QbD/Lean approaches to dissolution testing, impurity methods, method lifecycle (development/validation/transfer) and instrument qualification, and is passionate about using good science and sound logic to achieve high quality results, consistent with cGMPs, while minimizing resources. He is also past chair of the AAPS In Vitro Release and Dissolution Testing Focus Group. Mr. Martin is author of several papers in the areas of dissolution and analytical method validation.

Follow us :
ComplianceOnline Banking Summit 2016 | Risk Management and Data Security - 80390SEM
ComplianceOnline Medical Device Summit 2017

Product Reviews

This product hasn't received any reviews yet. Be the first to review this product! Write review

Best Sellers
You Recently Viewed
    Loading